Latest Close
$1.90
Stock Hub
PROK
ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
$1.19 (+167.23%)
Market Cap
$572,340,480.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
buy
52W Range
$0.46 to $7.13
Target Mean Price
$6.25
Beta
1.86
Trailing P/E
Not available
Forward P/E
-2.61
Price / Book
Not available
Company Overview
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.